Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
A new class of EGFR PROTACs based on pomalidomide was developed, synthesised, and tested for their cytotoxic activity against a panel of human cancer cells. Compounds 15–21 were showed to be more effective against the four tested cell lines than erlotinib. In particular, compound 16 was found to be...
Saved in:
| Main Authors: | Moustafa O. Aboelez, Amany Belal, Guangya Xiang, Xiang Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2022.2062338 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M
by: Ahmed A. Gaber, et al.
Published: (2022-12-01) -
Identification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
by: Bingnan Wang, et al.
Published: (2025-02-01) -
Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01) -
The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01) -
Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)